RxSight (RXST) Other Non Operating Income (2022 - 2024)

RxSight's (RXST) quarterly Other Non Operating Income came in at -$1.4 million in Q3 2023, down 288.67% on a QoQ basis from -$362000.0 in Q2 2023.

RxSight (RXST) Other Non Operating Income (2022 - 2024) Analysis & Trends

RxSight (RXST) has 2 years of Other Non Operating Income data on file, last reported at -$1.4 million in Q3 2023.

Quarterly Other Non Operating Income changed N/A year-over-year to -$1.4 million in Q3 2023, while the trailing twelve-month figure through Sep 2024 was -$1.4 million (down 181.4% YoY) and the FY2025 annual result came in at $272000.0, changed N/A from the prior year.
Other Non Operating Income eased to -$1.4 million in Q3 2023, from -$362000.0 in the prior quarter.
In the past five years, Other Non Operating Income ranged from a high of $1.3 million in Q4 2022 to a low of -$1.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	200.20 Bn	194.60 Bn	7.27 Bn
2	Stryker	129.69 Bn	126.21 Bn	4.50 Bn
3	Medtronic	120.14 Bn	110.92 Bn	6.41 Bn
4	Boston Scientific	74.16 Bn	73.62 Bn	3.85 Bn
5	Edwards Lifesciences	52.68 Bn	48.43 Bn	1.35 Bn
6	Dexcom	34.57 Bn	32.62 Bn	830.00 Mn
7	GE HealthCare Technologies	34.09 Bn	31.98 Bn	2.18 Bn
8	Koninklijke Philips	26.49 Bn	23.17 Bn	4.55 Bn
9	Steris	23.19 Bn	22.70 Bn	684.20 Mn
10	RxSight	251.23 Mn	-153.02 Mn	-

Download Data